Trial Profile
A Phase 3, Randomized, Study of Neoadjuvant Chemotherapy Alone Versus Neoadjuvant Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Post- Surgery Therapy With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle- Invasive Bladder Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 08 Apr 2024
Price :
$35
*
At a glance
- Drugs Linrodostat (Primary) ; Nivolumab (Primary) ; Cisplatin; Gemcitabine
- Indications Bladder cancer
- Focus Registrational; Therapeutic Use
- Sponsors Bristol-Myers Squibb; Ono Pharmaceutical
- 29 Jan 2024 Planned primary completion date changed from 3 Nov 2023 to 4 Apr 2025.
- 25 Jan 2023 Status changed from recruiting to active, no longer recruiting.
- 03 Nov 2022 Planned End Date changed from 15 Jan 2025 to 30 Dec 2027.